Area of research
Psychiatry and Mental health · Pharmacology
Research interest
Research interests include Schizophrenia research and treatment, Bipolar Disorder and Treatment, Treatment of Major Depression, and Tryptophan and brain disorders.
Moral Injury and the Global Health Workforce Crisis — Insights from an International Partnership
The influence of burnout on cardiovascular disease: a systematic review and meta-analysis
The hidden crisis: Moral injury among French healthcare workers
The impact of schizophrenia genetic load and heavy cannabis use on the risk of psychotic disorder in the EU-GEI case-control and UK Biobank studies
Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression
Adjunctive agents to antipsychotics in schizophrenia: a systematic umbrella review and recommendations for amino acids, hormonal therapies and anti-inflammatory drugs
Poverty and inequality in real-world schizophrenia: a national study
Exploring the mediation of DNA methylation across the epigenome between childhood adversity and First Episode of Psychosis—findings from the EU-GEI study
Association of severe mental illness and septic shock case fatality rate in patients admitted to the intensive care unit: A national population-based cohort study
Comparative analysis of anticholinergic burden scales to explain iatrogenic cognitive impairment and self-reported side effects in the euthymic phase of bipolar disorders: Results from the FACE-BD cohort
Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case–Control Study
Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study
Associations of white blood cell and platelet counts with specific depressive symptom dimensions in patients with bipolar disorder: Analysis of data from the FACE-BD cohort
Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study
Cognitive functioning throughout adulthood and illness stages in individuals with psychotic disorders and their unaffected siblings
The Independent Effects of Psychosocial Stressors on Subclinical Psychosis: Findings From the Multinational EU-GEI Study
The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study
The EUropean Network of National Schizophrenia Networks Studying Gene–Environment Interactions (EU-GEI): Incidence and First-Episode Case–Control Programme
Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case–control study
Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study
Metabolic and psychiatric effects of acyl coenzyme A binding protein (ACBP)/diazepam binding inhibitor (DBI)
Improving social function with real-world social-cognitive remediation in schizophrenia: Results from the RemedRugby quasi-experimental trial
Clinical guidelines for the management of treatment-resistant depression: French recommendations from experts, the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental
Clinical guidelines for the management of depression with specific comorbid psychiatric conditions French recommendations from experts (the French Association for Biological Psychiatry and Neuropsychopharmacology and the fondation FondaMental)
Pharmacotherapeutic approaches to treating depression during the perimenopause
Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study
Chronic low-grade peripheral inflammation is associated with ultra resistant schizophrenia. Results from the FACE-SZ cohort
Remission of depression in patients with schizophrenia and comorbid major depressive disorder: results from the FACE-SZ cohort
Latent toxoplasma infection in real-world schizophrenia: Results from the national FACE-SZ cohort
Machine learning for predicting psychotic relapse at 2 years in schizophrenia in the national FACE-SZ cohort